FS-8002 / Parr Biotechnology - LARVOL DELTA

FS-8002, a bifunctional antibody fusion protein of anti-VEGF and anti-TGF-β, exhibits significant anti-tumor activity in preclinical studies (AACR 2025) - "FS-8002 exhibited significant anti-tumor effect in two "cold tumor" xenograft models (human PBMC reconstituted MDA-MB-231 model and HT-29 cells model) as single agent or in combination with anti-PD-1 antibody (Keytruda®). All the preclinical data supported FS-8002 to be studied in clinical trials."

Preclinical • Oncology • TGFB1

Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002 (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Shanghai Pushi Medical Science Co. Ltd | Trial completion date: Sep 2026 ➔ Feb 2028 | Trial primary completion date: Sep 2026 ➔ Feb 2028

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002 (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Shanghai Pushi Medical Science Co. Ltd | Trial primary completion date: Sep 2025 ➔ Sep 2026

Trial primary completion date • Solid Tumor

Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002 (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Shanghai Pushi Medical Science Co. Ltd | Not yet recruiting ➔ Recruiting | N=86 ➔ 54

Enrollment change • Enrollment open • Oncology • Solid Tumor